Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Dec 12, 2023

BUY
$2.15 - $3.49 $1.13 Million - $1.83 Million
523,394 New
523,394 $1.2 Million
Q2 2023

Aug 08, 2023

SELL
$2.15 - $3.49 $423,225 - $687,003
-196,849 Reduced 27.33%
523,394 $1.2 Million
Q1 2023

Dec 12, 2023

BUY
$1.99 - $2.68 $1.29 Million - $1.74 Million
649,726 New
649,726 $1.58 Million
Q4 2022

Feb 03, 2023

BUY
$1.8 - $2.56 $206,487 - $293,670
114,715 Added 18.94%
720,243 $1.38 Million
Q2 2022

Aug 09, 2022

BUY
$1.31 - $2.69 $310,907 - $638,428
237,334 Added 64.46%
605,528 $1.13 Million
Q1 2022

May 05, 2022

BUY
$1.95 - $3.89 $384,976 - $767,979
197,424 Added 115.61%
368,194 $770,000
Q4 2021

Feb 02, 2022

BUY
$3.81 - $6.16 $650,633 - $1.05 Million
170,770 New
170,770 $673,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $157M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.